These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12001033)

  • 1. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy.
    Smith KY
    J Infect Dis; 2002 May; 185 Suppl 2():S123-7. PubMed ID: 12001033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection.
    Holstein A; Plaschke A; Egberts EH
    Exp Clin Endocrinol Diabetes; 2001; 109(8):389-92. PubMed ID: 11748485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection.
    Samaras K
    J Antimicrob Chemother; 2008 Feb; 61(2):238-45. PubMed ID: 18070830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
    Leonard EG; McComsey GA
    Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Metabolic disorders and lipodystrophy. Adverse effects of antiretroviral therapy].
    Goebel FD; Westner I
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():40-4. PubMed ID: 11373778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lactic acidosis in HIV patients receiving highly active antiretroviral therapy.
    Chow YW; Leong CL; Chow HL; Hooi LS
    Med J Malaysia; 2007 Mar; 62(1):78-80. PubMed ID: 17682581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
    Calza L; Manfredi R; Chiodo F
    J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly active antiretroviral HIV therapy-associated fatal lactic acidosis: quantitative and qualitative mitochondrial DNA lesions with mitochondrial dysfunction in multiple organs.
    Thoden J; Lebrecht D; Venhoff N; Neumann J; Müller K; Walker UA
    AIDS; 2008 May; 22(9):1093-4. PubMed ID: 18520357
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of Tris-hydroxymethyl aminomethane in severe lactic acidosis due to highly active antiretroviral therapy: a case report.
    Marfo K; Garala M; Kvetan V; Gasperino J
    J Clin Pharm Ther; 2009 Feb; 34(1):119-23. PubMed ID: 19125910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic effects of protease inhibitor therapy.
    Bernasconi E
    AIDS Read; 1999 Jul; 9(4):254-6, 259-60, 266-9. PubMed ID: 12737115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].
    Neumann T; Kondratieva J; Eggebrecht H; Wieneke H; Esser S; Bartel T; Erbel R
    Herz; 2005 Sep; 30(6):504-9. PubMed ID: 16170681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic complications of antiretroviral therapy.
    Sweet DE
    Top HIV Med; 2005; 13(2):70-4. PubMed ID: 16082057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HAART-associated body habitus and metabolic changes, Part 2.
    Liss M; Boyle BA
    AIDS Read; 2000 Dec; 10(12):688-91. PubMed ID: 11189733
    [No Abstract]   [Full Text] [Related]  

  • 16. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.
    Dubé MP; Stein JH; Aberg JA; Fichtenbaum CJ; Gerber JG; Tashima KT; Henry WK; Currier JS; Sprecher D; Glesby MJ; ;
    Clin Infect Dis; 2003 Sep; 37(5):613-27. PubMed ID: 12942391
    [No Abstract]   [Full Text] [Related]  

  • 17. Evidence for mitochondrial toxicity: lactic acidosis as proof of concept.
    Brinkman K
    J HIV Ther; 2001 Mar; 6(1):13-6. PubMed ID: 11501196
    [No Abstract]   [Full Text] [Related]  

  • 18. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic consideration for the use of antiretroviral agents in the elderly.
    Rhee MS; Greenblatt DJ
    J Clin Pharmacol; 2008 Oct; 48(10):1212-25. PubMed ID: 18812611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.